Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 461Melanoma 300Squamous Cell Carcinoma of Head and Neck 234Parkinson Disease 4, Autosomal Dominant Lewy Body 189Neoplasms 185Breast Neoplasms 162Triple Negative Breast Neoplasms 161Neoplasm Metastasis 156Lung Neoplasms 146Colorectal Neoplasms 142Carcinoma, Renal Cell 132Head and Neck Neoplasms 123Stomach Neoplasms 104Ovarian Neoplasms 100Carcinoma, Transitional Cell 91Urinary Bladder Neoplasms 81Pancreatic Neoplasms 81Carcinoma, Hepatocellular 74Endometrial Neoplasms 72Uterine Cervical Neoplasms 63Esophageal Neoplasms 57Recurrence 52Prostatic Neoplasms 49Sarcoma 43Carcinoma 42Glioblastoma 40Carcinoma, Squamous Cell 39Small Cell Lung Carcinoma 38Hodgkin Disease 36Cholangiocarcinoma 35

Interventions

pembrolizumab 1pamiparib 1famitinib 1enzalutamide 1apalutamide 1abiraterone 1Prednisone 1Prednisolone 1Poly(ADP-ribose) Polymerase Inhibitors 1Neoadjuvant Therapy 1Folfox protocol 1Fluorouracil 1Drug Therapy 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoadjuvant Therapy × pembrolizumab × Clear all
NCT05352165 2022-04-28

The Clinical Efficacy of Drug Sensitive Neoadjuvant Chemotherapy Based on Organoid Versus Traditional Neoadjuvant Chemotherapy in Advanced Rectal Cancer

Shanghai Minimally Invasive Surgery Center

Phase NA Unknown
192 enrolled

Neoadjuvant Therapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡